Thermo Fisher Scientific would be accelerating it’s efforts with diagnostic testing and vaccine development technologies to effectively manage COVID-19 outbreak in the country. The US Food and Drug Administration gave the company Emergency Use Authorization (EUA) for its TaqPathCOVID-19 Combo Kit for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, nasopharyngeal aspirate, and bronchoalveolar lavage (BAL).
In India, the relevant government organizations as well as private laboratories are working with Thermo Fisher to support scale up for testing. Real Time PCR instruments are being used to perform these tests. The company is well-positioned to cater to the growing requirement of conducting more tests as situation evolves.
“Thermo Fisher Scientific in India is geared to support COVID-19 testing initiatives to ensure priority access to instruments, consumables, safety supplies and other products to rapidly and efficiently respond to the outbreak. We are carefully managing our inventory, production and supply chains to ensure we continue to manufacture and deliver the products and services our customers rely on. It is times like these that reinforce our commitment to our mission which is to enable our customers to make the world healthier, cleaner and safer”, said Amit Chopra, Managing Director, India and Middle East, Thermo Fisher Scientific.